Famotidine
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support is soliciting proposals for a national requirements contract to supply Famotidine tablets in various dosages and counts. This is a firm-fixed-price requirements contract with a one-year base and four one-year options. The acquisition includes various small business set-aside provisions. Proposals are due October 11, 2022, at 3:00 PM EST.
Scope of Work
This solicitation seeks to establish a national supply source for Famotidine tablets, specifically:
- Famotidine 20 MG tablets in 25, 30, 50, 90, 180, and 1000 count bottles.
- Famotidine 40 MG tablets in 100, 180, and 1000 count bottles. These products will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through DLA and VA prime vendor programs.
Contract Details
- Type: Firm-Fixed-Price Requirements Contract (FAR Part 12, Commercial Item).
- Duration: One base year with four one-year options, for a maximum term of five years.
- Set-Aside: Includes various small business set-aside provisions (e.g., HUBZone, Service-Disabled Veteran-Owned Small Business, Economically Disadvantaged Women-Owned Small Business).
- Key Requirements:
- Products must be registered with RXNorm, First Data Bank, and Medi-Span.
- Unit of use packaging must be child-proof with specific bottle/label dimensions.
- Bar code labeling (GS1-128 or HIBCC) at the unit-of-use package level.
- Offerors must provide FDA approval (NDA, ANDA, or Biologic License).
- Manufacturing facilities must meet FDA current Good Manufacturing Practices (cGMP).
- Performance: Contract Price Effective Date no more than 60 days after award; Performance Date 45 days after award.
Submission & Evaluation
- Submission Deadline: October 11, 2022, 3:00 PM EST.
- Submission Method: Electronically via DLA Bid Board System (DIBBS).
- Evaluation Criteria: Lowest Price Technically Acceptable (LPTA) acquisition. Proposals will be evaluated for technical acceptability and lowest evaluated aggregate price.
- Proposal Structure: Offerors must submit a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2).
- Offer Acceptance: 90 calendar days from the date specified for receipt of offers.
- Other: A reverse auction may be utilized for price discussions.
Additional Notes
Awardee must enter into business-to-business agreements with DLA and VA Pharmaceutical Prime Vendor (PPV) contractors. Payments will be received from PPV contractors, not directly from the Government. A 0.5% cost recovery fee is embedded in contract prices. Interested parties should monitor DIBBS and Sam.Gov for the solicitation and any further updates. Contact Kristen Baraniewicz (kristen.baraniewicz@dla.mil) for questions.